Nxera Pharma
- Biotech or pharma, therapeutic R&D
Nxera Pharma (formerly Sosei Heptares) is a fully-integrated, technology-powered biopharma company, listed on the Tokyo Stock Exchange. We are world-leaders in the design and development of drugs targeting G protein-coupled receptors (GPCRs) and the partner of choice to develop and commercialize your innovative drugs in Japan & wider APAC. Seeking in-licensing and out-licensing opportunities with annual revenues of US$200 million and a healthy cash balance of US$240 million.



